NVO ▼ -6.1% - Novo Nordisk A/S $NVO Novo Nordisk Capital Markets Day: CEO Says Wegovy Pill Has Reached 7M U.S. Prescriptions as Company Expands Beyond Obesity ? • CEO says the Wegovy pill has reached 7M prescriptions in the U.S. and that Novo has “gained market share quite a bit” over recent months. • Novo plans to strengthen diabetes care while further diversifying into liver disease, cardiovascular and a new Blood & Endocrine Disorders segment. • An additional 4,000 personnel exits bring total downsizing tied to the operational unification to 13,000 employees. Novo Nordisk shares fell 6.1% despite the company reporting 7 million U.S. prescriptions for Wegovy's oral formulation and plans to expand beyond obesity into diabetes, liver disease, cardiovascular, and blood disorders. The decline may reflect investor concern over the announcement of an additional 4,000 job cuts as part of the company's operational restructuring, bringing total planned exits to 13,000 employees. 21-SEP-2026 05:26 AM ET